Navigation Links
Researchers Offer Explanation for Actos Bladder Cancer Risk
Date:7/3/2012

Orlando, FL (PRWEB) July 03, 2012

The Actos Bladder Cancer Center is alerting patients who have taken the drug Actos for their diabetes that researchers have identified an explanation for the drug’s link to bladder cancer. Legal help is still available for those just discovering they have been affected.

Anyone who has experienced symptoms of bladder cancer after taking Actos is encouraged to visit their doctor and speak with a lawyer about their legal rights as soon as possible.

For over a year, drug safety experts have warned that long-term use of Actos may be associated with bladder cancer. On June 10, 2011, CBS News reported that Germany and France banned Actos prescriptions after a study indicated long-term use could increase bladder cancer occurrences by as much as 40%. The FDA followed up on June 15, 2011 by issuing its own alert about the drug.

This April, the Canadian Press also reported that Health Canada had issued a warning after a study there showed a greater than 40% increased risk of bladder cancer from Actos.

Most recently, the British Medical Journal published a study on May 31, 2012 by researchers at McGill University in Montreal showing the increased bladder cancer risks from long-term Actos use may actually be as high as 83%.

The study found that the risk was specific to those taking Actos, and increased with use of the drug for more than two years. Also, this study was the first to specifically propose why Actos may increase risks of bladder cancer.

According to the research team at McGill, a possible explanatory mechanism for Actos bladder cancer risk is chronic irritation of the bladder from crystal formation caused by the drug. However, they cautioned that further research will be needed to establish this as causative.

Anyone who has suffered a bladder cancer or heart attack side effect after taking Actos is urged to speak with a lawyer about their legal options. According to Bloomberg News on March 13, 2012, Takeda Pharmaceuticals could face as many as 10,000 lawsuits in the U.S. from patients suffering serious side effects from their drug.

A federal Judicial Panel has consolidated all Actos lawsuits to a special multi-district federal court in Louisiana. The case is known as In Re: Actos Products Liability Litigation, MDL 2299, U.S. District Court, Western District of Louisiana (Lafayette).

The Actos Resource Center cautions that, while the MDL court will expedite litigation for victims, it is important for anyone affected to choose a lawyer with experience in this specific type of case. The Actos Resource Center works only with qualified Actos lawyers who are actively involved in this litigation and have handled thousands of cases.

For more information on the research, warnings, side effects, a possible actos class action lawsuit and legal options relating to the drug Actos, or to speak with a lawyer, visit http://www.ActosLawsuitUpdate.com.

Read the full story at http://www.prweb.com/releases/actos/lawsuit/prweb9663606.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. NIH awards $20 million over 5 years to train next generation of global health researchers
2. Researchers develop a new cell and animal model of inflammatory breast cancer
3. Researchers uncover a viable way for colorectal cancer patients to overcome drug resistance
4. Researchers Find Gene Mutations That May Be a Key to Autism
5. Researchers find evidence of banned antibiotics in poultry products
6. NJ stroke researchers report advances in spatial neglect research at AAN Conference
7. Autism by the numbers: Yale researchers examine impact of new diagnostic criteria
8. Researchers Map Brain Regions Linked to Intelligence
9. Researchers ID Genes That May Determine Mental Illness
10. Researchers Develop Blood Test for Depression
11. University of Cincinnati researchers win $3.7M grant from US Department of Defense
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and ... of published author, William Nowers. Captain Nowers and his wife, Millie, have six ... years in the Navy. Following his career as a naval aviator and carrier ...
(Date:10/12/2017)... WAUSAU, Wis. (PRWEB) , ... October 12, 2017 ... ... formulated standard products to meet the demand of today’s consumer and regulatory authorities ... team of probiotic experts and tested to meet the highest standard. , ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: , ... to enable prevention of a major side effect of chemotherapy in children. Cisplatin ... patients. For cisplatin, hearing loss is FDA listed on-label as a dose limiting ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the Health & Wellness ... Moonlight to raise money for the American Heart Association Heart Walk. Teams of up ... work together to keep their treadmills moving for 5 hours. Treadmills will start at ...
(Date:10/12/2017)... ... 2017 , ... Vohra Chief Medical Officer Dr. Shark Bird, ... nursing facility medical directors and other clinicians at various events in October. His ... many of these conferences we get to educate other physicians, facility nurses, corporate ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... and NEW YORK , Sept. 27, 2017  DarioHealth ... and big data solutions, today announced that its MyDario product is expected ... local TV listings for when The Dr. Oz Show airs in your ... The nine-time Emmy ... ...
(Date:9/23/2017)... 2017 Janssen Biotech, Inc. (Janssen) announced today ... the U.S. Food and Drug Administration (FDA) for the ... the treatment of moderately to severely active rheumatoid arthritis ... are needed to further evaluate the safety of sirukumab ... "We are ...
(Date:9/19/2017)... HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that ... developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and ...
Breaking Medicine Technology: